Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up
Posted inHematology-Oncology Specialties

Lisocabtagene Maraleucel Shows Durable Superior Efficacy Over Standard Therapy in Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year TRANSFORM Study Follow-Up

Three-year follow-up from the phase III TRANSFORM trial confirms lisocabtagene maraleucel (liso-cel) significantly improves event-free survival and response durability over standard of care in second-line relapsed/refractory large B-cell lymphoma with a favorable safety profile.
Telephone-Based Weight Loss Intervention Enhances Outcomes in Women With Stage II/III Breast Cancer: Insights From the BWEL Trial and Complementary Studies
Posted innews OB/GYN & Women's Health Oncology Specialties

Telephone-Based Weight Loss Intervention Enhances Outcomes in Women With Stage II/III Breast Cancer: Insights From the BWEL Trial and Complementary Studies

A phase 3 trial demonstrates that a telephone-based lifestyle intervention achieves clinically significant weight loss in women with stage II/III breast cancer and overweight/obesity, with notable effectiveness across demographics, especially in postmenopausal women.
Antibiotic Exposure as a Major Risk Factor for Clostridioides difficile Infection: Evidence from a Large Israeli Cohort and Systematic Reviews
Posted inCritical Care Gastroenterology Specialties

Antibiotic Exposure as a Major Risk Factor for Clostridioides difficile Infection: Evidence from a Large Israeli Cohort and Systematic Reviews

Recent research confirms that antibiotic exposure doubles the risk of hospital-onset Clostridioides difficile infection (CDI), especially in non-carriers, underscoring the central role of antibiotic stewardship and the need for additional preventive strategies in asymptomatic carriers.
Diverging Pediatric Recommendations on COVID-19 Vaccination: The AAP Advocates Routine Immunization for Young Children Amid Federal Policy Shift
Posted inAllergy & Immunology Infectious Diseases Pediatrics Public Health Specialties

Diverging Pediatric Recommendations on COVID-19 Vaccination: The AAP Advocates Routine Immunization for Young Children Amid Federal Policy Shift

The American Academy of Pediatrics recommends COVID-19 vaccination for all young children aged 6-23 months, diverging from current CDC policies that advise shared decision-making for healthy children. This review analyzes epidemiologic data, guideline conflicts, and implications for pediatric COVID-19 vaccine policies.